... of routine noninvasive diagnostic methods. Summary: Treatment options for PH-ILDs are limited and target mainly the underlying parenchymal lung disease. For decades, clinical trials of PH-ILD treatment using pulmonary vasodilators have failed showing no benefits or even harm. Thus, most PH-specific therapies...

...Lukas Ley; Pascal Klingenberger; Jürgen Hetzel; Tamara Schlitter; Hossein Ardeschir Ghofrani; Jens Allendörfer; Dirk Bandorski Introduction: Post-tracheostomy tracheal stenosis is a clinically relevant late complication of tracheostomy. To date, there is no standardized treatment strategy for post...

...Satenik Harutyunova; Nicola Benjamin; Christina Eichstaedt; Alberto M. Marra; Panagiota Xanthouli; Christian Nagel; Ekkehard Grünig; Benjamin Egenlauf Background: Current guidelines recommend treatment with parenteral prostacyclin analogs in patients with severe pulmonary arterial hypertension (PAH...

...Jessica M Aguilar Diaz; Ahmed A Abulfathi; Lindsey HM te Brake; Jakko van Ingen; Saskia Kuipers; Cecile Magis-Escurra; Jelmer Raaijmakers; Elin M Svensson; Martin J Boeree Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6 months), poor patient adherence, high...

... Chrysikos; Elli Malakounidou; Fotios Sampsonas; Demosthenes Bouros; Argyrios Tzouvelekis Introduction: Treatment of interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) often includes systemic corticosteroids. Use of steroid-sparing agents is amenable to avoid potential side...

...Paola Faverio; Martina Piluso; Federica De Giacomi; Matteo Della Zoppa; Roberto Cassandro; Sergio Harari; Fabrizio Luppi; Alberto Pesci Background: The prevalence and natural history of progressive fibrosing interstitial lung diseases (PF-ILDs), and their response to commonly used treatments...

..., instructions or products referred to in the content or advertisements. Nintedanib Pirfenidone Interstitial lung disease Therapeutics Treatment Mortality Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrosing interstitial lung disease (ILD) characterized by the presence...

... domain; and (d) have more exacerbations. Treatment of ACO and COPD patients differed from that of asthmatics, but not from each other, in the proportion of subjects on maintenance treatment, use of LABA, LAMA, and ICS, alone or in combination, and in the number of inhaler devices used by patients...

... survival rate of only 3 years and no curative pharmacological therapy. The recent approval of 2 anti-fibrotic drugs (nintedanib and pirfenidone) that slow disease progression has provided some hope for patients. However, effectively managing anti-fibrotic treatment can be a challenge due to tolerability...

... are not standardized at present. The first-line treatment for mild to moderate histoplasmosis, paracoccidioidomycosis, blastomycosis, sporotrichosis, and talaromycosis is itraconazole. Severe illness is treated with amphotericin B. Patients with severe coccidioidomycosis should receive fluconazole. Treatment duration...

... not always receive optimal treatment. To improve the management of patients with chronic obstructive pulmonary disease in Switzerland, these recommendations encourage a more comprehensive assessment of patients, based on the combined assessment of symptoms, degree of airflow limitation, risk of exacerbation...

...) in resource-rich settings and the growing number of non-HIV-infected immunocompromised patients at risk leads to considerable epidemiologic changes with clinical, diagnostic, and treatment consequences for physicians. HIV-infected patients usually develop a subacute course of disease, while non-HIV-infected...

... Diagnosis Therapy Treatment Swiss guidelines Asthma is a chronic respiratory disease, usually associated with airway inflammation and airway hyperresponsiveness (AHR) to a multitude of stimuli. These abnormalities tend to persist even if symptoms are absent and lung function is normal, although...

... Française Background: New therapies have emerged in the treatment of pulmonary alveolar proteinosis (PAP) and, therefore, there is a real need to evaluate the efficacy of whole-lung lavage (WLL) in this rare disease. Objectives: The aim of this study was to assess the efficacy of WLL in patients with PAP...

..., with significant comorbidities, such as lung diseases, lung cancer, diabetes mellitus, and immunosuppression. It is probable that such patients are at a higher risk to fail antibiotic treatment and require a drainage procedure [ 9 ]. In 4 patients (27%), attempts to culture the causative organism were...

... mortality in the years following diagnosis. There is no consensus on the optimal treatment. We report a case of a 63-year-old woman who presented with a diffuse tracheobronchial amyloidosis associated with laryngeal involvement, which required a percutaneous tracheostomy due to high-grade subglottic...

..., the kind of lung involvement and the risk associated with the clinical state of the patient and prognostic factors. Although several therapeutic approaches have been used, the best treatment is still not certain; clinical trials are mandatory, which would require a better knowledge of the pulmonary...

... as well as a safety cohort of 9 subsequent cases decided to continue the imatinib therapy. After adjusting the target international normalized ratio (INR) to around 2.0, no further cases of SDH occurred during 50 patient-years. Conclusions: Long-term treatment with imatinib may improve the functional...

... disease, on treatment outcomes and long-term survival in patients with multidrug-resistant forms of tuberculosis (MDR-TB). Objectives: We analyzed outcomes in a large cohort to assess the impact of DM on treatment outcomes of patients with MDR-TB. Methods: MDR-TB patients newly diagnosed or retreated...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Chronic obstructive pulmonary disease Diagnosis Treatment Management Swiss Guidelines Chronic obstructive pulmonary disease (COPD) is a leading cause of chronic...